Fisher Asset Management LLC Boosts Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Fisher Asset Management LLC increased its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 20.5% in the 3rd quarter, Holdings Channel.com reports. The firm owned 855,328 shares of the biopharmaceutical company’s stock after buying an additional 145,416 shares during the quarter. Fisher Asset Management LLC’s holdings in Agios Pharmaceuticals were worth $38,002,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Acadian Asset Management LLC bought a new position in Agios Pharmaceuticals in the 2nd quarter worth about $37,000. Quest Partners LLC purchased a new position in Agios Pharmaceuticals during the second quarter valued at approximately $40,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Agios Pharmaceuticals by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 363 shares during the period. CWM LLC increased its holdings in Agios Pharmaceuticals by 554.7% during the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $96,000 after acquiring an additional 1,836 shares during the period. Finally, North Star Asset Management Inc. purchased a new stake in Agios Pharmaceuticals in the 2nd quarter worth approximately $216,000.

Agios Pharmaceuticals Price Performance

Shares of AGIO opened at $59.10 on Wednesday. Agios Pharmaceuticals, Inc. has a 1 year low of $20.96 and a 1 year high of $62.58. The stock has a 50 day simple moving average of $47.66 and a two-hundred day simple moving average of $44.86. The firm has a market cap of $3.37 billion, a P/E ratio of 5.22 and a beta of 0.75.

Wall Street Analyst Weigh In

A number of research firms have recently commented on AGIO. Royal Bank of Canada restated an “outperform” rating and set a $55.00 price target on shares of Agios Pharmaceuticals in a research report on Friday, November 1st. Leerink Partnrs lowered Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 27th. Raymond James reiterated an “outperform” rating and set a $51.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Leerink Partners cut shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $60.00 to $56.00 in a research report on Friday, September 27th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Friday, September 20th. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $52.33.

Insider Activity

In other news, CFO Cecilia Jones sold 2,542 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the transaction, the chief financial officer now owns 20,158 shares in the company, valued at approximately $988,346.74. The trade was a 11.20 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.93% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.